<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2021-13-4-127-132</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-1279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинический случай</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical Case</subject></subj-group></article-categories><title-group><article-title>Дебют генерализованной миастении после перенесенной новой коронавирусной инфекции (COVID-19)</article-title><trans-title-group xml:lang="en"><trans-title>New onset of generalized myasthenia gravis developed after a new coronavirus infection (COVID-19)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующая кафедрой неврологии и психиатрии, ведущий научный сотрудник НИЛ цереброваскулярной патологии НИО неврологии и нейрореабилитации, д.м.н., доцент,</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">alekseeva_tm@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исабекова</surname><given-names>П. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Isabekova</surname><given-names>P. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры неврологии и психиатрии,</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">isabekova_p@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Топузова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Topuzova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры неврологии и психиатрии, старший научный сотрудник НИЛ цереброваскулярной патологии НИО неврологии и нейрореабилитации, к.м.н., доцент,</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">topuzova_mp@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скрипченко</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Skripchenko</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> заместитель директора по научной работе;</p><p>заведующая кафедрой инфекционных заболеваний у детей ФП и ДПО,</p><p>д.м.н., профессор, заслуженный деятель науки РФ,</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Saint-Petersburg</p></bio><email xlink:type="simple">rmtc@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр имени B.A. Алмaзoвa</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre named after V.A. Almazov</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Детский научно-клинический центр инфекционных болезней;&#13;
Санкт-Петербургский государственный педиатрический медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pediatric Research and Clinical Center for Infectious Diseases;&#13;
Saint-Petersburg State Pediatric Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>27</day><month>12</month><year>2021</year></pub-date><volume>13</volume><issue>4</issue><fpage>127</fpage><lpage>132</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Алексеева Т.М., Исабекова П.Ш., Топузова М.П., Скрипченко Н.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Алексеева Т.М., Исабекова П.Ш., Топузова М.П., Скрипченко Н.В.</copyright-holder><copyright-holder xml:lang="en">Alekseeva T.M., Isabekova P.S., Topuzova M.P., Skripchenko N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/1279">https://journal.niidi.ru/jofin/article/view/1279</self-uri><abstract><p>В период пандемии новой коронавирусной инфекции (COVID-19) особое внимание исследователей и врачей привлекает факт развития различных иммуноопосредованных неврологических осложнений после перенесенной вирусной инфекции. Было обнаружено, что SARS-CoV-2 обладает способностью вызывать гиперстимуляцию иммунной системы, тем самым инициируя развитие аутоиммунных заболеваний. В статье описан клинический случай дебюта генерализованной миастении с тимомой у пациента после перенесенной новой коронавирусной инфекции (COVID-19). </p></abstract><trans-abstract xml:lang="en"><p>Development of various immune-mediated neurological complications after a viral infection is of particular interest to medical society during a pandemic of COVID-19. It was found that SARS-CoV-2 has the ability to cause hyperstimulation of the immune system, thereby initiating developing of autoimmune diseases. The article describes a clinical case of new onset of generalized myasthenia gravis with thymoma in a patient after previous COVID-19. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>миастения</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>тимома</kwd><kwd>аутоиммунные заболевания</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myasthenia gravis</kwd><kwd>new coronavirus infection</kwd><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>thymoma</kwd><kwd>autoimmune diseases</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ruan Q. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [Electronic resource] / Ruan Q. [et al.] // Intensive Care Medicine. — 2020. — Vol. 46, № 5. — P. 846-848.</mixed-citation><mixed-citation xml:lang="en">Ruan Q. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [Electronic resource] / Ruan Q. [et al.] // Intensive Care Medicine. — 2020. — Vol. 46, № 5. — P. 846-848.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rojas M. Molecular mimicry and autoimmunity [Electronic resource] / M. Rojas [et al.] // Journal of Autoimmunity. — 2018. — Vol. 95. — P. 100-123.</mixed-citation><mixed-citation xml:lang="en">Rojas M. Molecular mimicry and autoimmunity [Electronic resource] / M. Rojas [et al.] // Journal of Autoimmunity. — 2018. — Vol. 95. — P. 100-123.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vojdani A. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases [Electronic resource] / Vojdani A., Kharrazian D. // Clinical Immunology. — 2020. — Vol. 217. — P. 108480.</mixed-citation><mixed-citation xml:lang="en">Vojdani A. Potential antigenic cross-reactivity between SARSCoV-2 and human tissue with a possible link to an increase in autoimmune diseases [Electronic resource] / Vojdani A., Kharrazian D. // Clinical Immunology. — 2020. — Vol. 217. — P. 108480.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vanderlugt C. L. Epitope spreading in immune-mediated diseases: implications for immunotherapy [Electronic resource] / Vanderlugt C.L., Miller S.D. // Nature Reviews Immunology. — 2002. — Vol. 2, № 2. — P. 85-95.</mixed-citation><mixed-citation xml:lang="en">Vanderlugt C. L. Epitope spreading in immune-mediated diseases: implications for immunotherapy [Electronic resource] / Vanderlugt C.L., Miller S.D. // Nature Reviews Immunology. — 2002. — Vol. 2, № 2. — P. 85-95.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ercolini A. M. The role of infections in autoimmune disease [Electronic resource] / Ercolini A.M., Miller S.D. // Clinical &amp; Experimental Immunology. — 2009. — Vol. 155, № 1. — P. 1-15.</mixed-citation><mixed-citation xml:lang="en">Ercolini A. M. The role of infections in autoimmune disease [Electronic resource] / Ercolini A.M., Miller S.D. // Clinical &amp; Experimental Immunology. — 2009. — Vol. 155, № 1. — P. 1-15.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Киселева, Е.П. Молекулярные механизмы инициирования и модуляции аутоиммунного процесса микроорганизмами / Е.П. Киселева [и др.] // Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. – 2021. – № 20 (1). – С. 99–113.</mixed-citation><mixed-citation xml:lang="en">Kiseleva E.P. Molekulyarny`e mexanizmy` iniciirovaniya i modulyacii autoimmunnogo processa mikroorganizmami / Kiseleva E.P., Mixajlopulo K.I., Novik G.I. // Voprosy` gematologii/onkologii i immunopatologii v pediatrii. – 2021. – T. 20, №1. – S. 99-113 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kim D. The Architecture of SARS-CoV-2 Transcriptome [Electronic resource] / Kim D. [et al.] // Cell. — 2020. — Vol. 181, № 4. — P. 914-921.</mixed-citation><mixed-citation xml:lang="en">Kim D. The Architecture of SARS-CoV-2 Transcriptome [Electronic resource] / Kim D. [et al.] // Cell. — 2020. — Vol. 181, № 4. — P. 914-921.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Català A. Maculopapular eruptions associated to COVID-9: A subanalysis of the COVID-Piel study [Electronic resource] / Català A. [et al.] // Dermatologic Therapy. — 2020. — Vol. 33, №6.</mixed-citation><mixed-citation xml:lang="en">Català A. Maculopapular eruptions associated to COVID-19: A subanalysis of the COVID-Piel study [Electronic resource] / Català A. [et al.] // Dermatologic Therapy. — 2020. — Vol. 33, № 6.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cao Y. Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GMCSF and Diminished IL-10 Production [Electronic resource] / Cao Y. [et al.] // The Journal of Immunology. — 2016. — Vol. 196, № 5. — P. 2075-2084.</mixed-citation><mixed-citation xml:lang="en">Cao Y. Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GMCSF and Diminished IL-10 Production [Electronic resource] / Cao Y. [et al.] // The Journal of Immunology. — 2016. — Vol. 196, № 5. — P. 2075-2084.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia [Electronic resource] / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol. 40, №6. Р. 1577–1589.</mixed-citation><mixed-citation xml:lang="en">Liu R. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia [Electronic resource] / Liu R. [et al.] // Eur J Immunol. – 2010. – Vol. 40, №6. Р. 1577–1589.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W. [et al.] // Cell Mol Immunol. – 2020. – Vol. 17. P. 650–652.</mixed-citation><mixed-citation xml:lang="en">Wang W. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients / Wang W. [et al.] // Cell Mol Immunol. – 2020. – Vol. 17. P. 650–652.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Romero-Sanchez C.M. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry / Romero-Sanchez C.M. [et al.] // Neurology. – 2020. – Vol. 95. P. 1060–1070.</mixed-citation><mixed-citation xml:lang="en">Romero-Sanchez C.M. Neurologic manifestations in hospitalized patients with COVID-19: the ALBACOVID registry / Romero-Sanchez C.M. [et al.] // Neurology. – 2020. – Vol. 95. P. 1060–1070.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Willison H.J. Guillain-Barré syndrome / Willison H.J., Jacobs B.C., van Doorn P.A. // Lancet. – 2016. – Vol. 13, №388. Р. 717-727.</mixed-citation><mixed-citation xml:lang="en">Willison H.J. Guillain-Barré syndrome / Willison H.J., Jacobs B.C., van Doorn P.A. // Lancet. – 2016. – Vol. 13, №388. Р. 717-727.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S., Daimee M., Sultan S. // J Neurol. – 2021. – Vol. 268, №8. P. 2690-2696.</mixed-citation><mixed-citation xml:lang="en">Sriwastava S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review / Sriwastava S., Tandon M., Kataria S., Daimee M., Sultan S. // J Neurol. – 2021. – Vol. 268, №8. P. 2690-2696.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Huber M. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient [Electronic resource] / Huber M. [et al.] // Front Neurol. – 2020. – Vol. 6, №11.</mixed-citation><mixed-citation xml:lang="en">Huber M. Postinfectious Onset of Myasthenia Gravis in a COVID-19 Patient [Electronic resource] / Huber M. [et al.] // Front Neurol. – 2020. – Vol. 6, №11.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Restivo D.A. Myasthenia Gravis Associated With SARSCoV-2 Infection / Restivo D.A., Centonze D., Alesina A., Marchese-Ragona R. // Ann Intern Med. – 2020. – Vol. 15. P. 1027-1028.</mixed-citation><mixed-citation xml:lang="en">Restivo D.A. Myasthenia Gravis Associated With SARSCoV-2 Infection / Restivo D.A., Centonze D., Alesina A., Marchese-Ragona R. // Ann Intern Med. – 2020. – Vol. 15. P. 1027-1028.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Muhammed L. MuSK Antibody-Associated Myasthenia Gravis With SARS-CoV-2 Infection: A Case Report / Muhammed L., Baheerathan A., Cao M., Leite M.I., Viegas S. // Ann Intern Med. – 2021 – Vol. 12. P. 1298.</mixed-citation><mixed-citation xml:lang="en">Muhammed L. MuSK Antibody-Associated Myasthenia Gravis With SARS-CoV-2 Infection: A Case Report / Muhammed L., Baheerathan A., Cao M., Leite M.I., Viegas S. // Ann Intern Med. – 2021 – Vol. 12. P. 1298.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Assini A. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection / Assini A. [et al.] // Eur J Neurol. – 2021 – Vol. 28. P. 3537-3539.</mixed-citation><mixed-citation xml:lang="en">Assini A. Myasthenia gravis associated with anti-MuSK antibodies developed after SARS-CoV-2 infection / Assini A. [et al.] // Eur J Neurol. – 2021 – Vol. 28. P. 3537-3539.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» Версия 7 (03.06.2020)</mixed-citation><mixed-citation xml:lang="en">Temporary methodological recommendations «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)» Version 7 (03.06.2020) (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Diorio C. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2 / Diorio C. [et al.] // J. Clin. Invest. – 2020. Vol. 130. P. 5967– 5975.</mixed-citation><mixed-citation xml:lang="en">Diorio C. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2 / Diorio C. [et al.] // J. Clin. Invest. – 2020. Vol. 130. P. 5967– 5975.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Consiglio C.R. The immunology of multisystem inflammatory syndrome in children with COVID-19 / Consiglio C.R. [et al.] // Cell. – 2020. Vol. 183. P. 968-981.</mixed-citation><mixed-citation xml:lang="en">Consiglio C.R. The immunology of multisystem inflammatory syndrome in children with COVID-19 / Consiglio C.R. [et al.] // Cell. – 2020. Vol. 183. P. 968-981.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Лобзин, Ю.В. Педиатрический мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией: нерешенные проблемы / Ю.В. Лобзин [и др.] // Журнал инфектологии. – 2021. – Т. 13, №1. – С. 13–21.</mixed-citation><mixed-citation xml:lang="en">Lobzin Yu.V. Pediatricheskij mul`tisistemny`j vospalitel`ny`j sindrom, associirovanny`j s novoj koronavirusnoj infekciej: nereshenny`e problemy` / Lobzin Yu.V. [i dr.] // Zhurnal Infektologii. – 2021. – T. 13, №1. – S. 13-21 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
